Key result
Extracorporeal life support is a feasible and potentially life-saving intervention for drug-induced cardiovascular shock refractory to conventional treatments, though evidence remains limited to case reports.
Why the study?
Does extracorporeal life support improve survival in patients with severe drug-induced cardiovascular shock refractory to conventional treatment?
Does extracorporeal life support improve survival in patients with severe drug-induced cardiovascular shock refractory to conventional treatment?
Extracorporeal life support is a feasible and potentially life-saving intervention for drug-induced cardiovascular shock refractory to conventional therapy, though current evidence is limited to case reports and small series.
No takes yet. Share an insight, caveat, or question.
Hypothesis-generating for extracorporeal life support in refractory drug-induced shock; prospective trials needed to confirm survival benefit.
Baud et al. (2007) conducted a review in Drug-induced cardiotoxicity and cardiovascular shock. Extracorporeal life support (ECLS) and cardiopulmonary bypass (CPB) vs. Conventional supportive treatment was evaluated. Extracorporeal life support is a feasible and potentially life-saving intervention for drug-induced cardiovascular shock refractory to conventional treatments, though evidence remains limited to case reports.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: